| Literature DB >> 26028024 |
L Golmard1,2, C Delnatte3, A Laugé1, V Moncoutier1, C Lefol1, K Abidallah1, H Tenreiro1, F Copigny1, M Giraudeau1, C Guy1, C Barbaroux1, G Amorim1, A Briaux1, V Guibert3, J Tarabeux1,2, S Caputo1, A Collet1, P Gesta4, O Ingster5, M-H Stern1,2, E Rouleau1, A de Pauw1, M Gauthier-Villars1, B Buecher1, S Bézieau3,6, D Stoppa-Lyonnet1,2,7, C Houdayer1,2,8.
Abstract
BRCA1 and BRCA2 are the two major genes predisposing to breast and ovarian cancer. Whereas high de novo mutation rates have been demonstrated for several genes, only 11 cases of de novo BRCA1/2 mutations have been reported to date and the BRCA1/2 de novo mutation rate remains unknown. The present study was designed to fill this gap based on a series of 12 805 consecutive unrelated patients diagnosed with breast and/or ovarian cancer who met the inclusion criteria for BRCA1/2 gene analysis according to French guidelines. BRCA1/2 mutations were detected in 1527 (12%) patients, and three BRCA1 mutations and one BRCA2 mutation were de novo. The BRCA1/2 de novo mutation rate was estimated to be 0.3% (0.1%; 0.7%). Although rare, it may be useful to take the possibility of de novo BRCA1/2 mutation into account in genetic counseling of relatives and to improve the understanding of complex family histories of breast and ovarian cancers.Entities:
Mesh：
Year: 2015 PMID： 26028024 DOI： 10.1038/onc.2015.181
Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867